BR112012032008A2 - anticorpos s100a4 e usos terapêuticos do mesmo - Google Patents

anticorpos s100a4 e usos terapêuticos do mesmo

Info

Publication number
BR112012032008A2
BR112012032008A2 BR112012032008A BR112012032008A BR112012032008A2 BR 112012032008 A2 BR112012032008 A2 BR 112012032008A2 BR 112012032008 A BR112012032008 A BR 112012032008A BR 112012032008 A BR112012032008 A BR 112012032008A BR 112012032008 A2 BR112012032008 A2 BR 112012032008A2
Authority
BR
Brazil
Prior art keywords
antibodies
therapeutic uses
therapeutic
preparing
methods
Prior art date
Application number
BR112012032008A
Other languages
English (en)
Other versions
BR112012032008B1 (pt
Inventor
Antonio Coll Manzano
Carme Clavis Calpe
Francesc Mitjans Prat
Jaume Adan Plana
Josep Maria Martínez Escolà
José Luis Hernández Míguez
Laura Barbera Ferrando
Laura Padilla García
Lourdes Tatiana Roque Navarro
Luis Angel Gomez Casajus
Manuel Rivas Cañas
Marc Masa Álvarez
Ramon Messeguer Peypoch
ROSA Mª HERVAS VILLEGAS
Sheila Dakhel Plaza
Original Assignee
Lykera Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43617041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012032008(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lykera Biomed Sa filed Critical Lykera Biomed Sa
Publication of BR112012032008A2 publication Critical patent/BR112012032008A2/pt
Publication of BR112012032008B1 publication Critical patent/BR112012032008B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)

Abstract

anticorpos s100a4 e usos terapêuticos do mesmo. a revelação refere-se a anticorpos contra s100a4, métodos para preparação desses anticorpos, composições farmacêuticas que compreendem esses anticorpos e usos terapêuticos e diagnósticos do mesmo.
BR112012032008-4A 2010-06-14 2011-06-14 Anticorpos s100a4, linhagem celular de hibridoma, composição farmacêutica, conjugado, método e kit para diagnosticar câncer ou uma doença associada à inflamação BR112012032008B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382170.8 2010-06-14
EP10382170 2010-06-14
PCT/EP2011/059868 WO2011157724A1 (en) 2010-06-14 2011-06-14 S100a4 antibodies and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
BR112012032008A2 true BR112012032008A2 (pt) 2016-10-04
BR112012032008B1 BR112012032008B1 (pt) 2020-05-26

Family

ID=43617041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032008-4A BR112012032008B1 (pt) 2010-06-14 2011-06-14 Anticorpos s100a4, linhagem celular de hibridoma, composição farmacêutica, conjugado, método e kit para diagnosticar câncer ou uma doença associada à inflamação

Country Status (21)

Country Link
US (2) US8916152B2 (pt)
EP (1) EP2580240B1 (pt)
JP (2) JP6081911B2 (pt)
KR (1) KR101869413B1 (pt)
CN (1) CN103201290B (pt)
AU (3) AU2011267089B2 (pt)
BR (1) BR112012032008B1 (pt)
CA (1) CA2802631C (pt)
CL (1) CL2012003538A1 (pt)
CY (1) CY1121742T1 (pt)
DK (1) DK2580240T3 (pt)
ES (1) ES2717908T3 (pt)
IL (1) IL223667B (pt)
LT (1) LT2580240T (pt)
MX (1) MX347734B (pt)
NZ (1) NZ604643A (pt)
PL (1) PL2580240T3 (pt)
PT (1) PT2580240T (pt)
RU (1) RU2615684C2 (pt)
TR (1) TR201903026T4 (pt)
WO (1) WO2011157724A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081911B2 (ja) * 2010-06-14 2017-02-15 リケラ バイオメッド エスエーＬｙｋｅｒａ Ｂｉｏｍｅｄ Ｓａ Ｓ１００ａ４抗体およびその治療上の使用
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
RU2484096C1 (ru) * 2012-02-08 2013-06-10 Общество с ограниченной ответственностью "Технофарма" ОДНОДОМЕННОЕ АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ БЕЛОК S100A4/Mts1, ПРИМЕНЕНИЕ ПОЛУЧЕННОГО АНТИТЕЛА ДЛЯ ДЕТЕКЦИИ ЭТОГО БЕЛКА
GB201219487D0 (en) 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
JP2014094919A (ja) * 2012-11-09 2014-05-22 Univ Of Fukui 腎炎の予防または治療剤
WO2014073653A1 (ja) * 2012-11-09 2014-05-15 国立大学法人福井大学 腎炎の病変部位の検査方法およびそのための試薬
ES2639227T3 (es) 2013-04-09 2017-10-25 Lykera Biomed S.A. Anticuerpos anti S100A7 para el tratamiento y diagnóstico de cáncer
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用
CN112083167B (zh) * 2019-06-14 2024-03-26 复旦大学附属华山医院 S100a4作为评估甲氨蝶呤干预银屑病的生物标记物及其用途
KR102151133B1 (ko) * 2019-12-27 2020-09-02 주식회사 인투앱 프로피오니박테리움 아크네스에 특이적으로 결합하는 신규한 항체 및 이의 용도
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
US20230220058A1 (en) 2020-06-30 2023-07-13 Arxx Therapeutics As Anti-S100A4 antibodies for the treatment of systemic sclerosis
JP2024509701A (ja) * 2021-02-09 2024-03-05 アークス セラピューティクス エーエス 抗ｓ１００ａ４ヒト化抗体、使用及び方法
CN113718029A (zh) * 2021-10-22 2021-11-30 中国人民解放军北部战区总医院 S100a4蛋白在动脉粥样硬化性肾动脉狭窄诊断中的应用
EP4433084A1 (en) * 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US6638504B1 (en) * 1990-07-09 2003-10-28 Research Corporation Technologies, Inc. Methods for treating cancer
EP0566571B1 (en) 1990-07-09 1997-05-07 Research Corporation Technologies, Inc. Diagnosis of metastatic cancer by the mts-1 gene
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
GB2294267B (en) 1993-06-03 1996-11-20 Therapeutic Antibodies Inc Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
DE19915485A1 (de) 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
WO2000064468A2 (en) * 1999-04-23 2000-11-02 Research Corporation Technologies Therapeutic compositions and methods for enhancing angiogenesis
NL1013865C2 (nl) 1999-12-16 2001-06-21 Haarman Innovation Man Bvba Werkwijze voor het bepalen van ten minste ÚÚn materiaal in een object, en apparaten voor de uitvoering daarvan.
DE10017249A1 (de) 2000-04-06 2001-10-11 Peter Solisch In-Vitro-Verfahren zur Feststellung bösartiger Tumore in der Human- und Veterinärmedizin
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
US20060270618A1 (en) 2001-12-18 2006-11-30 Dorian Bevec Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US20030165954A1 (en) 2002-01-09 2003-09-04 Third Wave Technologies, Inc. Cancer profiles
JP2004198419A (ja) 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
US20050208518A1 (en) 2003-05-16 2005-09-22 Longueville Francoise D Method and apparatus for determination of RNAi cell transfection effects by multiple gene expression analysis on micro-arrays
US20040229225A1 (en) 2003-05-16 2004-11-18 Jose Remacle Determination of a general three-dimensional status of a cell by multiple gene expression analysis on micro-arrays
CA2530506A1 (en) 2003-07-04 2005-01-13 Johnson & Johnson Research Pty. Limited Method for detection of alkylated cytosine in dna
WO2005012569A1 (en) 2003-08-01 2005-02-10 The University Of Western Australia Methods and kits for predicting the likelihood of successful treatment of cancer
US20080039413A1 (en) 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
JP2007537717A (ja) 2004-01-07 2007-12-27 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US20080193932A1 (en) 2004-11-05 2008-08-14 University Of Rochester Methods Of Inhibiting the Activity of Hsp90 and/or Aryl Hydrocarbon Receptor
KR100664589B1 (ko) 2004-12-28 2007-01-04 김현기 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 및이를 포함하는 발현 벡터
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
US20060269948A1 (en) 2005-05-16 2006-11-30 Halloran Philip F Tissue rejection
US7666596B2 (en) 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
JP5984324B2 (ja) 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
EP2121740A2 (en) 2005-12-20 2009-11-25 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
TW200745556A (en) 2006-01-24 2007-12-16 Ind Tech Res Inst Biomarkers for liver fibrotic injury
JP2007263896A (ja) 2006-03-29 2007-10-11 Univ Nagoya 肺癌患者の術後予後予測のための生物マーカー及びその方法
US8080428B2 (en) 2006-04-28 2011-12-20 Singapore Health Services Pte Ltd. Investigation of mucosa dryness conditions
WO2008030278A2 (en) 2006-06-05 2008-03-13 Fred Hutchinson Cancer Research Center Assays for radiation exposure
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
WO2008037432A2 (en) 2006-09-27 2008-04-03 Charité - Universitätsmedizin Berlin METHODS FOR DIAGNOSING METASTASIS BY ANALYZING MUTATIONS IN β-CATENIN
WO2008069881A2 (en) 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
US20100184034A1 (en) 2006-11-13 2010-07-22 SOURCE PRECISION MEDICINE, INC d/b/a SOURCE MDX Gene Expression Profiling for Identification, Monitoring and Treatment of Lung Cancer
DE102006056784A1 (de) 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
WO2008073290A1 (en) 2006-12-08 2008-06-19 The Board Of Trustees Of The University Of Arkansas Tp53 gene expression and uses thereof
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
US9353415B2 (en) 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
US20080161203A1 (en) 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
EP2102356A2 (en) 2007-01-09 2009-09-23 Brystol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
US20100233691A1 (en) 2007-03-30 2010-09-16 Source Precision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer
US20100216137A1 (en) 2007-04-05 2010-08-26 SOURCE PRECISION MEDICINE, INC d/b/a SOURCE MDX Gene Expression Profiling for Identification, Monitoring and Treatment of Ovarian Cancer
AU2007353824A1 (en) 2007-04-06 2008-11-27 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of cervical cancer
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
WO2009046267A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
JP6081911B2 (ja) * 2010-06-14 2017-02-15 リケラ バイオメッド エスエーＬｙｋｅｒａ Ｂｉｏｍｅｄ Ｓａ Ｓ１００ａ４抗体およびその治療上の使用

Also Published As

Publication number Publication date
JP6564408B2 (ja) 2019-08-21
CA2802631A1 (en) 2011-12-22
PL2580240T4 (pl) 2020-03-31
US20150079097A1 (en) 2015-03-19
AU2017200281B2 (en) 2018-12-06
RU2615684C2 (ru) 2017-04-06
WO2011157724A1 (en) 2011-12-22
CN103201290A (zh) 2013-07-10
US20130101592A1 (en) 2013-04-25
EP2580240B1 (en) 2018-11-28
AU2011267089B2 (en) 2017-02-16
US8916152B2 (en) 2014-12-23
NZ604643A (en) 2015-04-24
MX347734B (es) 2017-05-11
KR20130137583A (ko) 2013-12-17
TR201903026T4 (tr) 2019-04-22
KR101869413B1 (ko) 2018-06-20
AU2018264107A1 (en) 2018-12-06
JP2017101050A (ja) 2017-06-08
DK2580240T3 (en) 2019-03-25
CY1121742T1 (el) 2020-07-31
CA2802631C (en) 2019-12-17
JP2013531655A (ja) 2013-08-08
CN103201290B (zh) 2016-09-28
PL2580240T3 (pl) 2020-03-31
US9657092B2 (en) 2017-05-23
RU2013101529A (ru) 2014-07-20
ES2717908T3 (es) 2019-06-26
LT2580240T (lt) 2019-06-10
AU2017200281A1 (en) 2017-02-02
PT2580240T (pt) 2019-03-29
CL2012003538A1 (es) 2014-02-14
BR112012032008B1 (pt) 2020-05-26
IL223667B (en) 2018-03-29
AU2011267089A1 (en) 2013-01-17
MX2012014678A (es) 2013-02-26
JP6081911B2 (ja) 2017-02-15
EP2580240A1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
UY35210A (es) Inhibidores de autotaxina
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
ECSP10010295A (es) Formulacion de anticuerpo
MX2016008448A (es) Conjugados de var2csa-farmaco.
MA34091B1 (fr) Anticorps anti-cd40
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
BR112012021296A2 (pt) imunoconjugados e anticorpos de receptor de folato 1 e usos dos mesmos.
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
MX356210B (es) Formulaciones de polimero acrilico.
BR112015015368A2 (pt) composições de absorventes de dejetos de animais revestidas debaixa densidade
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
UY33833A (es) Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
BR112013020359A2 (pt) colágeno gelificável e meios para a sua provisão
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2011, OBSERVADAS AS CONDICOES LEGAIS.